In a report released today, from Jefferies maintained a Buy rating on Bristol-Myers Squibb, with a price target of $68.00. In addition to Jefferies......

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opus Genetics (IRD – Research Report), Bristol-Myers......

Jefferies analyst maintained a Buy rating on Bristol-Myers Squibb today and set a price target of $68.00. In addition to Jefferies, Bristol-Myers S......

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Acrivon Therapeutics, Inc. (ACRV – Research Report......

Bristol-Myers Squibb ( ($BMY) ) has shared an update. On November 10, 2025, BMS Ireland Capital Funding, a subsidiary of Bristol-Myers Squibb, comp......

With the S&P 500 ($SPX) up 22.8% over the past six months and the Nasdaq ($NDX) surging an even stronger 36.0%, there’s no denying that equities ar......

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb today and set a price target of $47.00. The company’s shares op......

Bristol-Myers Squibb ( ($BMY) ) has shared an announcement. On November 3, 2025, Bristol-Myers Squibb announced the commencement of cash tender off......

In a report released today, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Bristol-Myers Squibb, with a price target of $45.00. Th......

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb is conducting a Pha......